The experimental drug lecanemab shows “potential” as an Alzheimer’s disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association with certain serious adverse events.

(SOURCE) https://www.cnn.com/2022/11/29/health/lecanemab-alzheimers-drug-study/index.html